Taken together, our results indicate an enterohepatic impairment of FXR signaling in NAFLD pigs, with dysregulation of FXR downstream metabolic and inflammatory pathways in the liver and reduced FXR-induced FGF19 synthesis in the DI. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.